Literature DB >> 21953074

CD44 is a biomarker associated with human prostate cancer radiation sensitivity.

WeiWei Xiao1, Peter H Graham, Carl A Power, Jingli Hao, John H Kearsley, Yong Li.   

Abstract

CD44 plays an important role in cancer metastasis, chemotherapy, and radiation resistance. The present study investigated the relationship of CD44 expression and radioresistance, and the potential mechanisms of CD44 in radiosensitivity using prostate cancer (CaP) cell lines. CD44 was knocked down in three CaP cell lines (PC-3, PC-3M-luc, and LNCaP) using small interfering RNA (siRNA) and clonogenic survival fractions after single dose irradiation were compared before and after CD44 knocking down (KD). The effect of radiation on cell cycle distribution was examined by flow cytometry and the cell cycle-related protein levels of phospho-Chk1 and phospho-Chk2 were ascertained by Western blotting. The expression of the DNA double strand break (DSB) marker-γH2AX was also quantified by immunofluorescence staining. Our results indicate that the down-regulation of CD44 enhanced radiosensitivity in PC-3, PC-3M-luc, and LNCaP CaP cells, the sensitizing enhancement ratio for these cell lines was 2.3, 1.3, and 1.5, respectively and that the delay of DNA DSB repair in low CD44-expressing KD CaP cells correlated with ineffective cell cycle arrest and the delayed phosphorylation of Chk1 and Chk2. These findings suggest that CD44 may be a valuable biomarker and a predictor of radiosensitivity in CaP treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953074     DOI: 10.1007/s10585-011-9423-7

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

1.  Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12.

Authors:  John J Coen; Kyounghwa Bae; Anthony L Zietman; Baldev Patel; William U Shipley; Jerry D Slater; Carl J Rossi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-06       Impact factor: 7.038

2.  WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells.

Authors:  Wendy A Woodward; Mercy S Chen; Fariba Behbod; Maria P Alfaro; Thomas A Buchholz; Jeffrey M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

Review 3.  DNA damage and cell cycle checkpoints.

Authors:  W K Kaufmann; R S Paules
Journal:  FASEB J       Date:  1996-02       Impact factor: 5.191

4.  Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region.

Authors:  Sanna-Mari Maula; Marjaana Luukkaa; Reidar Grénman; David Jackson; Sirpa Jalkanen; Raija Ristamäki
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

5.  CD44 expression predicts local recurrence after radiotherapy in larynx cancer.

Authors:  Monique C de Jong; Jimmy Pramana; Jacqueline E van der Wal; Martin Lacko; Carine J Peutz-Kootstra; Jos M de Jong; Robert P Takes; Johannes H Kaanders; Bernard F van der Laan; Jasper Wachters; Jeroen C Jansen; Coen R Rasch; Marie-Louise F van Velthuysen; Reidar Grénman; Frank J Hoebers; Ed Schuuring; Michiel W van den Brekel; Adrian C Begg
Journal:  Clin Cancer Res       Date:  2010-09-13       Impact factor: 12.531

6.  Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer.

Authors:  Jen-Tsun Lin; Tung-Hao Chang; Cheng-Shong Chang; Wen-Hong Wang; Bi-Wen Su; Kuan-Der Lee; Pey-Jium Chang
Journal:  Oral Oncol       Date:  2010-03-12       Impact factor: 5.337

7.  Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate.

Authors:  A C Gao; W Lou; J P Sleeman; J T Isaacs
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

8.  Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance.

Authors:  Lisa J Harper; Daniela Elena Costea; Luke Gammon; Bilal Fazil; Adrian Biddle; Ian C Mackenzie
Journal:  BMC Cancer       Date:  2010-04-28       Impact factor: 4.430

9.  Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.

Authors:  J Hao; H Chen; M C Madigan; P J Cozzi; J Beretov; W Xiao; W J Delprado; P J Russell; Y Li
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

10.  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Authors:  Kui Yang; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more
  15 in total

1.  Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance.

Authors:  C Alberti
Journal:  G Chir       Date:  2015 May-Jun

2.  Understanding the mechanism underlying the acquisition of radioresistance in human prostate cancer cells.

Authors:  Kosho Murata; Ryo Saga; Satoru Monzen; Echi Tsuruga; Kazuki Hasegawa; Yoichiro Hosokawa
Journal:  Oncol Lett       Date:  2019-04-05       Impact factor: 2.967

3.  Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.

Authors:  Ling Li; Xinbao Hao; Jun Qin; Wenhua Tang; Fengtian He; Amber Smith; Min Zhang; Diane M Simeone; Xiaotan T Qiao; Zhi-Nan Chen; Theodore S Lawrence; Liang Xu
Journal:  Gastroenterology       Date:  2014-01-05       Impact factor: 22.682

Review 4.  Opportunities and challenges of radiotherapy for treating cancer.

Authors:  Dörthe Schaue; William H McBride
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

5.  Identification, expansion and characterization of cancer cells with stem cell properties from head and neck squamous cell carcinomas.

Authors:  Hatem O Kaseb; Helene Fohrer-Ting; Dale W Lewis; Eric Lagasse; Susanne M Gollin
Journal:  Exp Cell Res       Date:  2016-09-09       Impact factor: 3.905

6.  Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels.

Authors:  Lisa A Gurski; Xian Xu; Lyana N Labrada; Ngoc T Nguyen; Longxi Xiao; Kenneth L van Golen; Xinqiao Jia; Mary C Farach-Carson
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

7.  Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.

Authors:  L Chang; P H Graham; J Hao; J Ni; J Bucci; P J Cozzi; J H Kearsley; Y Li
Journal:  Cell Death Dis       Date:  2013-10-24       Impact factor: 8.469

Review 8.  Cancer stem cells and signaling pathways in radioresistance.

Authors:  Lei Chang; Peter Graham; Jingli Hao; Jie Ni; Junli Deng; Joseph Bucci; David Malouf; David Gillatt; Yong Li
Journal:  Oncotarget       Date:  2016-03-08

9.  Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells.

Authors:  N McDermott; A Meunier; B Mooney; G Nortey; C Hernandez; S Hurley; N Lynam-Lennon; S H Barsoom; K J Bowman; B Marples; G D D Jones; L Marignol
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

10.  Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer.

Authors:  Filipe Pinto; Nelma Pértega-Gomes; José R Vizcaíno; Raquel P Andrade; Flavio M Cárcano; Rui Manuel Reis
Journal:  Oncotarget       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.